Search hospitals

>

Connecticut

>

New Haven

Yale University School of Medicine

Claim this profile

New Haven, Connecticut 06510

Global Leader in Alzheimer's Disease

Global Leader in Type 1 Diabetes

Conducts research for Cancer

Conducts research for Obesity

Conducts research for Lung Cancer

728 reported clinical trials

61 medical researchers

Photo of Yale University School of Medicine in New HavenPhoto of Yale University School of Medicine in New HavenPhoto of Yale University School of Medicine in New Haven

Summary

Yale University School of Medicine is a medical facility located in New Haven, Connecticut. This center is recognized for care of Alzheimer's Disease, Type 1 Diabetes, Cancer, Obesity, Lung Cancer and other specialties. Yale University School of Medicine is involved with conducting 728 clinical trials across 782 conditions. There are 61 research doctors associated with this hospital, such as Patricia M Lorusso, Alessandro Santin, Amer M. Zeidan, and Charles Matouk.

Area of expertise

1

Alzheimer's Disease

Global Leader

Yale University School of Medicine has run 52 trials for Alzheimer's Disease. Some of their research focus areas include:

PSEN2 positive
PSEN1 positive
APP positive
2

Type 1 Diabetes

Global Leader

Yale University School of Medicine has run 47 trials for Type 1 Diabetes. Some of their research focus areas include:

mIAA positive
IA-2A positive
ZnT8A positive

Top PIs

Clinical Trials running at Yale University School of Medicine

Ovarian Cancer

Cancer

Colorectal Cancer

Multiple Myeloma

Lung Cancer

Gastrointestinal Stromal Tumor

Relapse

Chronic Lymphocytic Leukemia

Breast Cancer

Stroke

Image of trial facility.

Heated Chemotherapy + Niraparib

for Ovarian Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease \>1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC Arm will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (No HIPEC Arm) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per standard institutional guidelines +/- bevacizumab for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing +/- bevacizumab until progression or 36 months (if no evidence of disease).

Recruiting

2 awards

Phase 3

Image of trial facility.

Rina-S

for Ovarian Cancer

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

LY3537982

for Cancer

This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.

Recruiting

1 award

Phase 1 & 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Yale University School of Medicine?

Where is Yale University School of Medicine located?

Who should I call to ask about financial aid or insurance network?

What insurance does Yale University School of Medicine accept?

What awards or recognition has Yale University School of Medicine received?